By
Andrew Young, Amylin Pharmaceuticals Inc., San Diego, CA, USA
Description
Deciphers amylin's physiology and reveals previously unrecognized mechanisms fundamental to control body weight and fuel homeostasis.
Also discusses therapeutic utility of amylin as the first new medicine to treat diabetes since insulin.
Included in series
Advances in Pharmacology
Audience:
Endocrinologists, pharmacologists, biochemists, neuroscientists